Our Development Pipeline


Topical Minocycline, 2%

BPX-01 (topical minocycline, 2%) is being developed for the treatment of moderate-to-severe acne. In a Phase 2b study, treatment with BPX-01 showed a statistically significant reduction in the number of acne lesions, with no serious adverse events related to study treatment. BPX-01 is a hydrophilic topical gel with fully solubilized minocycline capable of penetrating the skin to deliver the antibiotic to where acne develops in the pilosebaceous unit..

If you are interested in any of Timber’s ongoing clinical research programs, please contact trials@timberpharma.com.

 Legal Notice | © 2020 by Timber Pharmaceuticals LLC